TIDMAMYT
RNS Number : 9132Z
Amryt Pharma PLC
22 May 2019
22 May 2019
AIM: AMYT
Euronext Growth: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Grant of Options and Notification of Transactions by Persons
Discharging Managerial Responsibilities
Amryt announces that the Remuneration Committee has approved the
grant of 3,407,734 share options ("Options") to subscribe for
ordinary shares of 1p each in the Company ("Shares") under the
Employee Share Option Plan 2016 (the "Plan") to Joe Wiley, CEO, and
Rory Nealon, CFO, details of which are set out in the table
below.
The Options have an exercise price of 12.64p ("Exercise Price").
These options may be exercised as follows:
-- 25% of the total Options granted may be exercised 12 months
after the date of grant;
-- a further 25% of the total Options granted may be exercised
24 months after the date of grant; and
-- the balance of the Options may be exercised 36 months
after the date of grant.
All Options are subject to change of control provisions and
expire on the seventh anniversary of their grant.
Following the grants of these options, the following Directors
have the following options:
Director Options granted Total Options now
held
Joe Wiley 1,896,239 3,957,369
---------------- ------------------
Rory Nealon 1,511,495 2,335,947
---------------- ------------------
PDMR Dealings
The notification of dealing forms for each Director can be found
below. This announcement is made in accordance with Article 19 of
the EU Market Abuse Regulation 596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Joe Wiley
------------------------------------- -----------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status Director
------------------------------------- -----------------------------------------------
b) Initial notification Initial notification
/ amendment
------------------------------------- -----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Amryt Pharma plc
------------------------------------- -----------------------------------------------
b) Legal entity identifier 213800BOS8WAJO2BEQ38
------------------------------------- -----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BDD1LS57
------------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of options under the Employee
Share Option Plan 2016 with an exercise
price of 12.64p to purchase 1,896,239
ordinary shares.
------------------------------------- -----------------------------------------------
c) Currency British Pounds
------------------------------------- -----------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- ---------------------- --------------------
N/A 1,896,239
----------------------------------------------------------------- --------------------
e) Aggregated information
* Aggregated volume 1,896,239
N/A
* Aggregated price
------------------------------------- -----------------------------------------------
f) Date of the transaction 21 May 2019
------------------------------------- -----------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Rory Nealon
------------------------------------- -----------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status Director
------------------------------------- -----------------------------------------------
b) Initial notification Initial notification
/ amendment
------------------------------------- -----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Amryt Pharma plc
------------------------------------- -----------------------------------------------
b) Legal entity identifier 213800BOS8WAJO2BEQ38
------------------------------------- -----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BDD1LS57
------------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of options under the Employee
Share Option Plan 2016 with an exercise
price of 12.64p to purchase 1,511,495
ordinary shares.
------------------------------------- -----------------------------------------------
c) Currency British Pounds
------------------------------------- -----------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- ---------------------- --------------------
N/A 1,511,495
----------------------------------------------------------------- --------------------
e) Aggregated information
* Aggregated volume 1,511,495
N/A
* Aggregated price
------------------------------------- -----------------------------------------------
f) Date of the transaction 21 May 2019
------------------------------------- -----------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Enquiries:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Financial Advisor, NOMAD and Joint
Broker
Edward Mansfield, Mark Percy, Daniel
Bush
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy +353 (1) 679 6363
Euronext Growth Advisor and Joint
Broker
John Frain, Daragh O'Reilly
Consilium Strategic Communications +44 (0) 20 3709 5700
Amber Fennell, Matthew Neal, David
Daley
About Amryt
Amryt is a biopharmaceutical company focused on developing and
delivering innovative new treatments to help improve the lives of
patients with rare or orphan diseases.
Lojuxta(R) is an approved treatment for adult patients with the
rare cholesterol disorder - Homozygous Familial
Hypercholesterolaemia ("HoFH"). This disorder impairs the body's
ability to remove low density lipoprotein ("LDL") cholesterol
("bad" cholesterol) from the blood, typically leading to abnormally
high blood LDL cholesterol levels in the body from before birth -
often ten times more than people without HoFH - and subsequent
aggressive and premature narrowing and blocking of blood vessels.
Lojuxta(R) is indicated as an adjunct to a low-fat diet and other
lipid-lowering medicinal products with or without LDL apheresis in
adult patients with HoFH.
Amryt is the marketing authorisation holder and has an exclusive
licence to sell Lojuxta(R) (lomitapide) across the European
Economic Area, Middle East and North Africa, Switzerland, Turkey,
Israel, Russia, the Commonwealth of Independent States and the
non-EU Balkan states.
Amryt's lead development candidate, AP101, is a potential
treatment for Epidermolysis Bullosa ("EB"), a rare and distressing
genetic skin disorder affecting young children and adults for which
there is currently no treatment. It is currently in Phase 3
clinical trials and recently reported positive unblinded interim
efficacy analysis results and is anticipated will be fully enrolled
by end of H2 2019. The European and US market opportunity for EB is
estimated to be in excess of $1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy
platform technology, AP103, which offers a potential treatment for
patients with Recessive Dystrophic Epidermolysis Bullosa, a subset
of EB, and is also potentially relevant to other genetic
disorders.
In May 2019, Amryt announced the planned acquisition of Aegerion
Pharmaceuticals. This Transaction will put Amryt on the path to
creating a rare and orphan disease company with a diversified
offering of multiple commercial and development stage assets and
will provide it with scale to support further growth. The
Transaction will give Amryt an expanded commercial footprint to
market two US and EU approved products, lomitapide (Juxtapid(R)
(US/ROW) / Lojuxta(R) (EU)) and metreleptin (Myalept(R) (US) /
Myalepta(R) (EU)). Amryt's leadership team already has a deep
knowledge of both these products and since December 2016 has
successfully commercialized Lojuxta(R) across Europe and the Middle
East.
For more information on Amryt, please visit
www.amrytpharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSEAFWEFUSEFI
(END) Dow Jones Newswires
May 22, 2019 13:24 ET (17:24 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2023 to Apr 2024
